

Amendments to the Claims:

This listing of amended claims was presented as part of the response after the Final Office Action mailed on May 20, 2003. The list is maintained without further amendment.

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition comprising a solid dispersion of fenofibrate, or a salt or ester thereof, and hydroxypropylmethylcellulose (HPMC) ~~polyvinylpyrrolidone (PVP)~~ crystallization inhibitor in a polyethylene glycol (PEG) carrier.
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Currently Amended) The composition of Claim 1 ~~2~~ wherein said solid dispersion is encapsulated in a hard gelatin capsule.
9. (Currently Amended) The composition of Claim 1 ~~2~~ wherein said solid dispersion is compressed into a tablet.
10. (Original) The composition of claim 1 further comprising an additive or a mixture of additives independently selected from the group consisting of pharmaceutically acceptable surfactants and antioxidants.
11. (Canceled)
12. (Canceled)
13. (Currently Amended) A method of preparing a composition of Claim 1, comprising the steps of:
 - a) dissolving a pharmaceutical compound and hydroxypropylmethylcellulose (HPMC) ~~polyvinylpyrrolidone~~ in an organic solvent to form a solution;
 - b) adding polyethylene glycol to said solution to form a mixture;
 - c) optionally flash evaporating said solvent;

- d) optionally drying the resulting residue remaining after evaporation;
 - e) optionally grinding and sieving the solid dispersion to obtain a resultant product.
14. (Original) The method of claim 13 additionally comprising encapsulating the solid dispersion in a hard gelatin capsule.
 15. (Original) The method of claim 13 additionally comprising compressing said solid dispersion into a tablet.
 16. (Canceled)
 17. (Canceled)
 18. (Original) The method of claim 13 wherein said solvent is ethanol.
 19. (Canceled)
 20. (Canceled)
 21. (Canceled)
 22. (Original) A method of treating hyperlipidemia comprising administering an effective amount of a solid dispersion of claim 1 to a mammal in need of such treatment, wherein said pharmaceutical compound is fenofibrate.
 23. (Canceled)